Orphan Therapeutics Acquires Full Rights To Terlipressin From PDL BioPharma
This article was originally published in The Pink Sheet Daily
The company will initiate a rolling NDA submission in Q2 2007 despite failure to meet novel primary endpoint, Orphan president tells “The Pink Sheet” DAILY.
You may also be interested in...
PDL is moving forward with Phase II development of the biologic in multiple sclerosis with partner Biogen Idec.
The biotech is “aggressively” seeking potential in-licensing opportunities and hopes to partner its heart failure agent ularitide in 2007.
Late-stage development compound was evaluated for treatment of type 1 hepatorenal syndrome.